Orexo discloses more information about the improved market access position for Zubsolv® US in 2018
Uppsala, Sweden – December 12, 2017 - Orexo AB today announces specific information about the improved market access position for Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) in the US effective January 1, 2018, and previously announced in the Interim Report for the third quarter of 2017. Recently the Formulary List of Covered Drugs for 2018 has been announced by all managed care programs, thus enabling Orexo to share more details about the 2018 formulary position for Zubsolv. Entering 2018, Zubsolv will have stronger market access position than ever in the US. In the